Drug Profile
SL 181616
Latest Information Update: 23 Nov 2001
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Melatonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders; Sleep disorders
Most Recent Events
- 23 Nov 2001 Discontinued-Preclinical for CNS disorders (Unknown route)
- 23 Nov 2001 Discontinued-Preclinical for Sleep disorders (Unknown route)
- 12 Feb 2001 Preclinical development for Sleep disorders (Unknown route)